Calistoga Pharmaceuticals has initiated a Phase I clinical trial of its lead compound, CAL-101, a small molecule phosphoinositide-3 kinase delta inhibitor, in patients with hematologic cancer.

Calistoga Pharmaceuticals has started a Phase I clinical trial of CAL-101, a novel orally-available small molecule inhibitor of an important intracellular signaling component known as phosphoinositide-3 kinase delta.

Calistoga Pharmaceuticals, a newly formed, privately held drug development company focused on developing novel therapies in oncology and inflammation announced today that it closed a successful Series A venture round of $21 million.